BRPI0520330A2 - adjuvante a base de ácido polinosìnico-policitidìlico - Google Patents

adjuvante a base de ácido polinosìnico-policitidìlico

Info

Publication number
BRPI0520330A2
BRPI0520330A2 BRPI0520330-9A BRPI0520330A BRPI0520330A2 BR PI0520330 A2 BRPI0520330 A2 BR PI0520330A2 BR PI0520330 A BRPI0520330 A BR PI0520330A BR PI0520330 A2 BRPI0520330 A2 BR PI0520330A2
Authority
BR
Brazil
Prior art keywords
adjuvant
immune response
present
polynositic
obtaining
Prior art date
Application number
BRPI0520330-9A
Other languages
English (en)
Inventor
Haixiang Lin
Original Assignee
Newbiomed Pika Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiomed Pika Pte Ltd filed Critical Newbiomed Pika Pte Ltd
Publication of BRPI0520330A2 publication Critical patent/BRPI0520330A2/pt
Publication of BRPI0520330B1 publication Critical patent/BRPI0520330B1/pt
Publication of BRPI0520330B8 publication Critical patent/BRPI0520330B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ADJUVANTE A BASE DE áCIDO POLINOSìNICO-POLICITIDìLICO. Mais particularmente a presente invenção refere-se a uma composição adjuvante polinucleotídica e métodos de uso para a obtenção de uma resposta imunológica. A presente invenção também se refere a uma composição imunogênica que compreende a composição adjuvante polinucleotídica em conjunto com um antigeno (por exemplo, na forma de uma vacina). As composições adjuvantes da invenção possuem propriedades fisicas específicas (por exemplo, peso molecular, concentração e pH) que abordam a necessidade de um adjuvante seguro para a obtenção de uma maior resposta imunológica. A presente invenção também contempla métodos de uso das referidas composições adjuvantes, especificamente para a obtenção de uma resposta imunológica a um composto antigênico.
BRPI0520330A 2005-06-08 2005-06-08 adjuvante a base de ácido polinosínico-policitidílico BRPI0520330B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/000810 WO2006131023A1 (en) 2005-06-08 2005-06-08 Polyinosinic acid-polycytidylic acid-based adjuvant

Publications (3)

Publication Number Publication Date
BRPI0520330A2 true BRPI0520330A2 (pt) 2009-05-05
BRPI0520330B1 BRPI0520330B1 (pt) 2018-04-24
BRPI0520330B8 BRPI0520330B8 (pt) 2021-05-25

Family

ID=37498098

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520330A BRPI0520330B8 (pt) 2005-06-08 2005-06-08 adjuvante a base de ácido polinosínico-policitidílico

Country Status (18)

Country Link
US (2) US7838017B2 (pt)
EP (1) EP1898948B1 (pt)
JP (1) JP2008542405A (pt)
KR (1) KR101203401B1 (pt)
CN (1) CN1997391A (pt)
AT (1) ATE539767T1 (pt)
AU (1) AU2005332599B2 (pt)
BR (1) BRPI0520330B8 (pt)
CA (1) CA2605583C (pt)
DK (1) DK1898948T3 (pt)
ES (1) ES2380481T3 (pt)
IL (1) IL187616A (pt)
MX (1) MX2007015639A (pt)
MY (1) MY146412A (pt)
PL (1) PL1898948T3 (pt)
RU (1) RU2383552C2 (pt)
WO (1) WO2006131023A1 (pt)
ZA (1) ZA200709747B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
US20090090367A1 (en) * 2007-10-03 2009-04-09 Hurley Scott B Method of contraception
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CN101890161B (zh) * 2008-10-07 2014-07-23 郝国荣 聚核苷酸组合物佐剂
CN101780279B (zh) * 2009-12-22 2012-07-11 中山大学中山眼科中心 Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
US9636414B2 (en) 2011-12-15 2017-05-02 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
US10172960B2 (en) 2011-12-15 2019-01-08 Biontech Ag Particles comprising single stranded RNA and double stranded RNA for immunomodulation
SG11201406208QA (en) 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
CN102949717A (zh) * 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016105274A1 (en) * 2014-12-23 2016-06-30 Yisheng Biopharma (Singapore) Pte Ltd A rabies composition comprising pika adjuvant
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
CN109125264B (zh) * 2017-06-19 2020-10-30 林海祥 一种抗感染抗肿瘤的粘膜免疫制剂
US11135286B2 (en) * 2017-08-10 2021-10-05 Yisheng Biopharma (Singapore) Pte Ltd Composition for treating and/or preventing Hepatitis B virus infection and the use thereof
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
CN109078180B (zh) * 2018-06-29 2019-05-31 信福(北京)医药科技有限公司 用于增强免疫响应的复合物
JP7296644B2 (ja) * 2018-06-29 2023-06-23 信福（北京）医▲薬▼科技有限公司 免疫応答を強化するための複合物の調製方法
CN109701011B (zh) * 2019-02-26 2022-04-05 苏文全 疫苗复合佐剂系统及其在抗原中的应用
AU2020299074B2 (en) 2019-07-02 2024-02-22 Na Vaccine Institute Novel ribonucleic acid and pharmaceutical composition based on the same
AU2021278137A1 (en) * 2020-05-29 2023-01-05 Beijing Yisheng Biotechnology Co., Ltd. Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19
WO2024102079A1 (en) * 2022-11-09 2024-05-16 Zeno Therapeutics Pte Ltd Compositions comprising polyinosinic-polycytidylic acid, epstein-barr (ebv) virus-like particles and ebv-specific car-t cells for improving immune cell therapy
JPWO2025028658A1 (pt) * 2023-08-03 2025-02-06
WO2026022256A1 (en) * 2024-07-24 2026-01-29 Institut National de la Santé et de la Recherche Médicale Gallium-apramycin complexes, methods of preparation thereof and their use in the treatment of bacterial infections
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3666646A (en) 1970-05-15 1972-05-30 Merck & Co Inc Reduction of molecular weight in polynucleotides using ultrasonic radiation
US4124702A (en) 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4186194A (en) 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2321896A1 (fr) 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4153684A (en) 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
US4082735A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
US4140761A (en) 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
JPS55111499A (en) 1979-02-21 1980-08-28 Takeda Chem Ind Ltd Glucosamine derivative and its preparation
CA1185237A (en) 1979-02-28 1985-04-09 Yuichi Yamamura 6-deoxyglucosamine-peptide derivatives, their production and use
NZ194880A (en) 1979-09-17 1983-07-15 Merck & Co Inc Interferon-inducing composition containing modified polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
FR2476488A2 (fr) * 1980-02-25 1981-08-28 Government Us America Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon
JPS572220A (en) * 1980-06-09 1982-01-07 Toray Ind Inc Production of interferon
US4389395A (en) 1981-01-09 1983-06-21 Lerner A Martin Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4857315A (en) * 1986-09-29 1989-08-15 Mount Sinai Hospital Corporation Compositions containing golgi alpha-mannosidase II inhibitors
JPH01186818A (ja) * 1988-01-18 1989-07-26 Yamasa Shoyu Co Ltd ポリリボイノシン酸・ポリリボシチジル酸・ポリ−ｌ−リジン複合体製剤
CN1056315C (zh) * 1993-05-31 2000-09-13 林海祥 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2004263037B2 (en) 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
AU2005238272A1 (en) * 2004-04-28 2005-11-10 Paradigm Therapeutics Limited Ion channel
KR101203401B1 (ko) * 2005-06-08 2012-11-22 이쉥 바이오파마(싱가포르)피티이 리미티드 폴리이노신산-폴리시티딜산-기초 보조제
US20070166800A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20070166239A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
RU2416411C2 (ru) * 2008-12-22 2011-04-20 Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" Способ лечения переломов длинных трубчатых костей

Also Published As

Publication number Publication date
EP1898948A4 (en) 2008-07-16
IL187616A0 (en) 2008-03-20
RU2383552C2 (ru) 2010-03-10
US20100297176A1 (en) 2010-11-25
AU2005332599B2 (en) 2012-02-16
CN1997391A (zh) 2007-07-11
US8303965B2 (en) 2012-11-06
WO2006131023A1 (en) 2006-12-14
ATE539767T1 (de) 2012-01-15
KR101203401B1 (ko) 2012-11-22
EP1898948B1 (en) 2012-01-04
AU2005332599A1 (en) 2006-12-14
BRPI0520330B8 (pt) 2021-05-25
CA2605583C (en) 2013-05-28
BRPI0520330B1 (pt) 2018-04-24
ZA200709747B (en) 2008-11-26
JP2008542405A (ja) 2008-11-27
PL1898948T3 (pl) 2012-06-29
EP1898948A1 (en) 2008-03-19
CA2605583A1 (en) 2006-12-14
KR20080016592A (ko) 2008-02-21
IL187616A (en) 2014-02-27
AU2005332599A8 (en) 2008-03-20
US20070160632A1 (en) 2007-07-12
US7838017B2 (en) 2010-11-23
ES2380481T3 (es) 2012-05-14
RU2007149551A (ru) 2009-07-10
MX2007015639A (es) 2008-02-15
MY146412A (en) 2012-08-15
DK1898948T3 (da) 2012-04-23

Similar Documents

Publication Publication Date Title
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
DK2068918T3 (da) Vaccinesammensætning omfattende syntetisk adjuvant
BRPI0607840A2 (pt) uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
CO6751288A2 (es) Composición antigénica de micobacteria
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BRPI0820258B8 (pt) composto, composições de vacina, e, uso de um composto
BR112015012968A2 (pt) composições e métodos de uso
CO6341568A2 (es) Composicion inmunologica
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
UY32876A (es) Régimen de inmunización por sensibilización-refuerzo heteróloga
BR112022002094A2 (pt) Composição imunogênica
CU23720A3 (es) Adyuvante basado en ácido poliinosínico-ácido policitidílico
BRPI0517124A (pt) composição farmacêutica e processo de preparação de uma composição
BR112017015288A2 (pt) vacina contra febre aftosa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: YISHENG BIOPHARMA (SINGAPORE) PTE LTD (SG)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.